MOLCURE Inc.
PrivateLast Round
Series C
Aug 18, 2021
Est. Valuation
$23.58M
Total Funding Raised
$13.7M
Company Overview
MOLCURE Inc. is a biotechnology company that provides an AI-driven platform for drug discovery, leveraging machine learning and a proprietary database to design and identify novel antibodies and peptides for pharmaceutical partners.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, ML Platforms
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MOLCURE Inc. Comparables
Compare MOLCURE Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| LabGenius Therapeutics | 86% | |
| Antiverse | 86% | |
| BigHat Biosciences | 85% |
MOLCURE Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 18, 2021 | ||||
| Series B | Nov 27, 2018 | ||||
| Grant | Sep 1, 2016 | ||||
| Series A | Sep 29, 2014 |
Key People
Founding team and executive leadership
MOLCURE Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| JAFCO Group Co., Ltd. | Series C |
| Japan Post Capital | Series C |
| UTEC (The University of Tokyo Edge Capital Partners) | Series A |
| New Energy and Industrial Technology Development Organization | Grant |
| GMO VenturePartners | Series B, Series C |
| Strive | Series C |
| STRIVE | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 1, 2026
Attending the AI:360 Conference in California in November 2026.
- Nov 1, 2026
Invited to present at the AI:360 Conference in November 2026.
Recent news
Latest coverage and updates
- attends_eventSep 24, 2026
Molcure will attend event BioJapan 2026 on Oct 7th '26.
- partners_withSep 8, 2026
Molcure partnered with Axcelead Group on Sep 8th '26.
- partners_withSep 8, 2026
Molcure partnered with Axcelead Drug Discovery Partners, Inc. on Sep 8th '26.
MOLCURE Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about MOLCURE Inc.'s valuation, stock price, and market status.
Is MOLCURE Inc. a public or private company?
MOLCURE Inc. is a private company.
What is the current stock price of MOLCURE Inc.?
MOLCURE Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is MOLCURE Inc. worth (valuation)?
MOLCURE Inc.'s valuation is estimated at $23.6M based on funding round data.
Can I buy MOLCURE Inc. stock?
MOLCURE Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was MOLCURE Inc.'s last funding round?
MOLCURE Inc.'s most recent funding round was Series C on August 18, 2021.
Who are the main investors in MOLCURE Inc.?
Key investors in MOLCURE Inc. include JAFCO Group Co., Ltd..
Will MOLCURE Inc. IPO soon?
No public IPO plans have been announced for MOLCURE Inc..
How can I track MOLCURE Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor MOLCURE Inc.'s secondary market activity and sign up for updates.